Quidelortho Corpoation ($QDEL) Stock Forecast: Down 6.1% Today

What is Quidelortho Corpoation?

QuidelOrtho Corporation (QDEL) is a company specializing in medical diagnostics, specifically recognized for its immunoassay analyzers and assays. Despite recent positive developments, the stock saw a downward trend today.

Why is Quidelortho Corpoation going down?

QDEL stock is down 6.1% on Mar 6, 2026 16:01

• American Century Companies Inc. and insiders have increased their holdings in QuidelOrtho, reflecting strong confidence in the company. However, analysts have given the stock a "Reduce" consensus rating, indicating doubts about its future prospects.
• Concerns surrounding revenue, cash flow, and return on invested capital have resulted in the stock underperforming compared to the market, despite surpassing earnings expectations. This underperformance likely contributed to the bearish movement.
• The new supply agreement with Lifotronic Technology aimed at expanding into international markets could serve as a positive driver. Yet, the overall weak long-term momentum and undervaluation point to persistent challenges impacting the stock negatively.
• Institutional selling by Segall Bryant & Hamill LLC has further fuelled the bearish sentiment, despite notable insider buying. The conflicting signals from insiders and institutions may have intensified the selling pressure on the stock.

QDEL Price Chart

QDEL Technical Analysis

QDEL News

American Century Companies Inc. Raises Stock Position in QuidelOrtho Corporation $QDEL

American Century Companies Inc. increased its stake in QuidelOrtho Corporation (NASDAQ:QDEL) by 10.4% in the third quarter, now owning over 2.1 million shares valued at approximately $62.3 million. Insiders also showed increased confidence, with CEO Brian J. Blaser and Director Matthew Strobeck acquiring a total of 20,540 shares in February. Despite beating Q3 earnings estimates with EPS of $0.46 and revenue of $723.6 million, QuidelOrtho faces a "Reduce" consensus rating from analysts with an average target price of $31.50.

https://www.marketbeat.com/instant-alerts/filing-american-century-companies-inc-raises-stock-position-in-quidelortho-corporation-qdel-2026-03-05/

QuidelOrtho Stock Challenges: Revenue, Cash Flow, and ROIC Trends - News and Statistics

Shares of QuidelOrtho have underperformed the S&P 500, showing a significant decline over the past six months due to concerns about revenue, cash flow, and return on invested capital. Analysts point to year-on-year revenue declines, negative free cash flow margins, and decreasing ROIC as major red flags. Despite a recent share price drop, the stock’s valuation is still considered to reflect optimistic expectations, suggesting better investment opportunities elsewhere.

https://www.indexbox.io/blog/quidelortho-stock-analysis-revenue-decline-and-profitability-concerns/

A Look At QuidelOrtho (QDEL) Valuation After New Lifotronic Supply Agreement

QuidelOrtho (QDEL) recently announced a new long-term supply agreement with Lifotronic Technology, giving it access to additional immunoassay analyzers and assays in select international markets. Despite recent stock gains, longer-term momentum has been weak, with a 1-year total shareholder return decline of 41.77%. Simply Wall St analysts suggest the stock is undervalued by 34.4%, with a fair value of $34.67 per share, speculating on future growth from international market expansion, although challenges like declining COVID testing remain.

https://www.sahmcapital.com/news/content/a-look-at-quidelortho-qdel-valuation-after-new-lifotronic-supply-agreement-2026-03-02

Segall Bryant & Hamill LLC Sells 71,044 Shares of QuidelOrtho Corporation $QDEL

Segall Bryant & Hamill LLC reduced its stake in QuidelOrtho Corporation by 5.5% in the third quarter, selling 71,044 shares and now holding 1,229,152 shares valued at $36.2 million. Despite beating earnings estimates with EPS of $0.46 and revenue of $723.6 million, QuidelOrtho reported a negative net margin and a "Reduce" consensus rating with a $31.50 target. Insider buying has occurred, with CEO Brian Blaser and CFO Joseph Busky purchasing shares, but institutional investors and hedge funds still own 99.00% of the company's stock.

https://www.marketbeat.com/instant-alerts/filing-segall-bryant-hamill-llc-sells-71044-shares-of-quidelortho-corporation-qdel-2026-03-03/

A Look At QuidelOrtho (QDEL) Valuation After New Lifotronic Supply Agreement

QuidelOrtho (QDEL) recently announced a long-term supply agreement with Lifotronic Technology, giving it access to additional immunoassay analyzers and assays in international markets. Despite a recent 7.31% gain, the stock has shown weak long-term momentum with a 41.77% decline over the past year. Simply Wall St's analysis suggests QuidelOrtho is 34.4% undervalued, with a fair value of $34.67 per share, based on its potential for global expansion in diagnostics and improved future earnings, though challenges like declining COVID testing remain.

https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/a-look-at-quidelortho-qdel-valuation-after-new-lifotronic-su

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.5% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

Quidelortho Corpoation Price History

03.02.2026 - QDEL Stock was down 5.5%

• A new supply agreement with Lifotronic Technology aimed at expanding its immunoassay offerings outside the U.S. may have initially attracted investor interest. However, concerns about the company's overall profitability and leadership transitions seem to have overshadowed this positive development.
• Vanguard Group Inc. reducing its stake in QuidelOrtho Corporation by 2.1% could be interpreted as indicating a lack of confidence in the company's future prospects, contributing to the downward trajectory of the stock.
• Despite surpassing quarterly earnings estimates, challenges such as a negative net margin, ongoing profitability issues, and an average "Reduce" recommendation from brokerages, along with a consensus price target of $31.50, have likely exerted downward pressure on the stock price.
• Insider acquisitions by CEO Brian J. Blaser and CFO Joseph M. Busky may have offered some support. However, with insiders collectively owning less than 1% of the company, this might not have been sufficient to counter the prevailing negative sentiment surrounding QuidelOrtho Corporation.

13.01.2026 - QDEL Stock was up 7.6%

• QDEL outperformed expectations for Q4 earnings and revenues, demonstrating a resilient performance amid differing forecasts for fiscal 2026.
• Despite challenges from reduced COVID-19 testing impacting respiratory revenues, QDEL saw strong growth in its non-respiratory Labs division and improved adjusted EBITDA margins through cost-saving measures.
• An estimated undervaluation of 24.9% and positive prospects related to the acquisition of LEX Diagnostics suggest promising opportunities for future growth.
• The surge in stock price may be linked to investor optimism surrounding QDEL's robust performance in labs expansion and positive revenue projections for 2026, outweighing concerns about declining respiratory revenues and cash flow challenges.

12.01.2026 - QDEL Stock was down 19.9%

• QuidelOrtho Corp (QDEL) revealed strong Q4 2025 earnings, driven by robust growth in non-respiratory Labs business. However, challenges arose due to a decline in respiratory revenue, especially from reduced COVID-19 testing.
• The company's lower-than-expected earnings per share forecast for 2026 potentially influenced the bearish market trend, dampening investor sentiment despite the positive Q4 results.
• Although QuidelOrtho Corp (QDEL) surpassed earnings projections and issued optimistic 2026 guidance, the stock dipped in after-hours trading, indicating investor apprehensions regarding broader market conditions or specific aspects of the forecast.
• The market response to the earnings release was mixed, with revenue surpassing predictions but full-year 2026 guidance falling short of analyst expectations. This disparity likely contributed to the slight stock price decrease and the observed bearish movement today.

25.01.2026 - QDEL Stock was up 11.2%

• The recent CEO termination at QuidelOrtho, followed by the appointment of interim executives, may have initially caused market uncertainty, but investors have reacted positively to these changes.
• Although Zacks Research downgraded QuidelOrtho to a "strong sell" rating, the increased holdings by CFO Joseph M. Busky and Director Matthew Strobeck could have boosted confidence in the company's future.
• The release of the company's annual Form 10-K report highlighted challenges like decreased revenues and a net loss, but strategic initiatives such as cost-reduction plans and enhanced R&D investments were mentioned, potentially mitigating concerns.
• QuidelOrtho's upcoming participation in the Raymond James Institutional Investor Conference might have sparked investor interest and optimism regarding the company's future trajectory, contributing to the bullish movement in the stock price.

20.01.2026 - QDEL Stock was down 6.5%

• QDEL was downgraded from a "hold" to a "strong sell" rating by Zacks Research, potentially impacting investor sentiment and contributing to the bearish movement.
• The release of QDEL's annual Form 10-K report showing a decrease in total revenues and a net loss, coupled with challenges from industry competition and regulatory risks, likely added to the negative market sentiment.
• Analyst questions during QDEL's Q4 earnings call regarding declining revenues, tariffs, and gross margin pressures may have further fueled the bearish movement as investors reacted to these concerns.
• The upcoming presentation at the Raymond James Institutional Investor Conference could provide an opportunity for QDEL to address these issues and potentially reverse the bearish trend by showcasing its strategies for future growth and profitability.

06.02.2026 - QDEL Stock was down 6.1%

• American Century Companies Inc. and insiders have increased their holdings in QuidelOrtho, reflecting strong confidence in the company. However, analysts have given the stock a "Reduce" consensus rating, indicating doubts about its future prospects.
• Concerns surrounding revenue, cash flow, and return on invested capital have resulted in the stock underperforming compared to the market, despite surpassing earnings expectations. This underperformance likely contributed to the bearish movement.
• The new supply agreement with Lifotronic Technology aimed at expanding into international markets could serve as a positive driver. Yet, the overall weak long-term momentum and undervaluation point to persistent challenges impacting the stock negatively.
• Institutional selling by Segall Bryant & Hamill LLC has further fuelled the bearish sentiment, despite notable insider buying. The conflicting signals from insiders and institutions may have intensified the selling pressure on the stock.

27.00.2026 - QDEL Stock was down 5.3%

• Financial concerns have arisen among investors due to QDEL's low Altman Z-Score of 0.2, negative earnings, and tight balance sheet, detracting attention from its primary diagnostics focus.
• Despite surpassing Q4 earnings projections, the company's negative net margin, mixed FY2025 guidance, and recent share buybacks by top executives have influenced the bearish market trend.
• The stock has faced a significant decline in share price, weakening margins, and a high Altman Z-Score indicating financial distress, resulting in an 11% decrease aggravated by market fluctuations.
• Investor views vary, with price valuations ranging from $38 to $84, underscoring uncertainty regarding QDEL's financial future amid its diagnostic activities and resilience in the blood-supply sector.

11.01.2026 - QDEL Stock was down 7.0%

• QuidelOrtho (QDEL) experienced a bearish movement today.
• The decline in QDEL's stock price could be attributed to the market's reaction to the news of the expected decline in earnings and revenues for the fourth quarter of 2025.
• The decision of director Matthew W. Strobeck to step down after the annual meeting might have also contributed to the negative sentiment surrounding the stock, despite the company's strong financial performance in the previous quarter.
• Investors may be concerned about the implications of the board reduction and the departure of a long-serving director on the company's future strategic direction, leading to the bearish trend in QDEL's stock price.

23.00.2026 - QDEL Stock was down 7.7%

• Shares of Company Q fell over 11% due to broader market pressures, reflecting concerns about financial challenges and sector-specific risks.
• Despite surpassing Q4 earnings estimates, Company Q reported a negative net margin and high leverage, impacting market sentiment.
• Analysts' views vary, with a price target increase to $35 indicating potential upside, but the stock remains volatile due to financial weakness and market conditions.
• The recent stock price decline emphasizes the importance of monitoring financial health and profitability for future performance.

04.01.2026 - QDEL Stock was up 5.2%

• QuidelOrtho (QDEL) experienced a strong bullish movement today, likely driven by positive factors such as:
• Anticipation of strong Q4 2025 earnings release, following the company's previous success in beating analyst estimates in Q3.
• Recognition for excellence in customer and technical services, as evidenced by receiving prestigious awards and certifications.
• Increased institutional ownership and insider buying, indicating growing confidence in the company's performance and potential.
• Potential value opportunity highlighted by analysts, suggesting that despite previous share price declines, the company may be undervalued based on fundamental metrics.

18.01.2026 - QDEL Stock was up 6.6%

• A strategic supply agreement with Lifotronic Technology Co., Ltd. to expand its global immunoassay portfolio and reach new markets outside the United States has likely boosted investor confidence in QuidelOrtho's growth prospects.
• The planned retirement of the Chief Financial Officer, while initially concerning, seems to have been overshadowed by the positive news of international expansion, indicating that investors are focusing more on the company's strategic direction rather than individual personnel changes.
• Despite mixed opinions from analysts following the recent earnings report, the company's ability to meet revenue guidance, expand EBITDA margins, and focus on stable growth in the Labs business amidst challenges has likely contributed to the bullish sentiment surrounding QDEL.
• Reassurance provided by the company regarding the CFO's retirement not being related to financial disagreements, coupled with the efforts to address risks and reduce leverage, may have instilled confidence in investors regarding QuidelOrtho's long-term financial stability and growth potential.

10.01.2026 - QDEL Stock was up 6.2%

• QuidelOrtho (QDEL) saw a strong bullish movement today, possibly influenced by the announcement of director Matthew W. Strobeck's decision to step down post-annual meeting.
• Strobeck's departure, due to other professional commitments, may have been viewed positively by investors, hinting at a strategic shift or new leadership opportunities within the company.
• The bullish trend may also be linked to QuidelOrtho's robust performance in the third quarter of 2025, surpassing analyst expectations in earnings per share, revenue, and a raised price target by UBS.
• The combination of strong financial results and a significant change in the company's leadership likely contributed to today's bullish movement in QuidelOrtho's stock.